Trastuzumab Deruxtecan Early HER2+ Breast Cancer — PatSnap Eureka
Trastuzumab Deruxtecan in Early-Stage HER2+ Breast Cancer
T-DXd (Enhertu) is moving from late-line rescue to early-stage treatment across the DESTINY-Breast phase III portfolio. Understand the patent landscape, combination strategies, and clinical trial positioning with PatSnap Eureka.
A Next-Generation ADC Redefining HER2-Targeted Therapy
Trastuzumab deruxtecan (T-DXd), marketed as Enhertu, is an antibody-drug conjugate (ADC) comprising an anti-HER2 antibody linked to the topoisomerase I inhibitor payload DXd (an exatecan derivative) via a tetrapeptide-based cleavable linker. Co-developed by Daiichi Sankyo and AstraZeneca, T-DXd is characterized by a drug-to-antibody ratio (DAR) of approximately 7–8, designed to optimize anti-tumor activity while maintaining acceptable toxicity profiles.
The tetrapeptide-based cleavable linker enables selective intracellular release of the cytotoxic payload within HER2-expressing cancer cells. A key differentiating feature is its bystander killing effect — released DXd can penetrate neighbouring HER2-low or HER2-negative cells, expanding activity beyond purely HER2-amplified tumours. This mechanism is the basis for T-DXd's activity in FDA-approved HER2-low indications and its ongoing expansion into early-stage disease.
The global patent estate for T-DXd, held predominantly by Daiichi Sankyo and AstraZeneca, now spans the core ADC composition, manufacturing processes, and an extensive portfolio of combination therapy strategies. As of 2024, life sciences patent intelligence tools reveal over 40 active combination patent families covering kinase inhibitors, immune checkpoint agents, DNA damage response inhibitors, endocrine therapies, and more.
According to ClinicalTrials.gov, the DESTINY-Breast programme encompasses multiple phase III trials evaluating T-DXd across the full breast cancer treatment continuum — from early-stage neoadjuvant and adjuvant settings through to first-line and later-line metastatic disease.
DESTINY-Breast Trials in Neoadjuvant and Adjuvant Settings
Patent filings from Daiichi Sankyo and AstraZeneca explicitly reference neoadjuvant therapy, adjuvant therapy, and combination regimens for early-stage HER2-positive and HER2-low breast cancer.
DESTINY-Breast05: Adjuvant T-DXd in Residual Disease
DESTINY-Breast05 is a pivotal phase III trial evaluating trastuzumab deruxtecan as adjuvant therapy in patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant chemotherapy. This addresses one of the highest-unmet-need populations in early HER2+ disease — patients who do not achieve pathological complete response (pCR) with standard neoadjuvant treatment.
Adjuvant · Post-NACT residual disease · HER2+DESTINY-Breast11: Neoadjuvant T-DXd in HER2+ and HER2-low
DESTINY-Breast11 investigates T-DXd in the neoadjuvant setting for both HER2-positive and HER2-low early breast cancer. This trial is significant because it extends T-DXd's reach beyond HER2-amplified disease into the broader HER2-low population — defined by immunohistochemical scores of 1+ or 2+ without FISH amplification — in the pre-surgical setting.
Neoadjuvant · HER2+ and HER2-low · Early BCT-DXd + Taxane: Documented Combination for Early-Stage Disease
Patent WO2024118784A1 (Daiichi Sankyo / AstraZeneca, June 2024) specifically claims a combination of an anti-HER2 ADC with a taxane for treating breast cancer, including early-stage HER2-positive breast cancer in neoadjuvant or adjuvant treatment settings. Taxane-backbone regimens are standard-of-care in early HER2+ disease, making this combination clinically relevant and strategically important.
WO2024118784A1 · Taxane combination · Filed June 2024T-DXd + Pertuzumab + Chemotherapy: Multi-Agent Neoadjuvant Strategies
Patent WO2024057314A1 (Daiichi Sankyo / AstraZeneca, March 2024) discloses combination treatment of breast cancer using T-DXd in combination with pertuzumab, chemotherapy, and/or endocrine therapies across neoadjuvant, adjuvant, and metastatic settings. Pertuzumab-based dual HER2 blockade is a cornerstone of current early HER2+ neoadjuvant therapy, and its combination with T-DXd represents a high-interest clinical strategy.
WO2024057314A1 · Pertuzumab + chemo · Filed March 2024T-DXd Combination Strategy Patent Landscape
Analysis of Daiichi Sankyo and AstraZeneca patent filings from 2022–2024 reveals the breadth and strategic direction of the T-DXd combination therapy pipeline.
T-DXd Combination Partners by Mechanistic Category
Kinase and cell cycle inhibitors dominate the documented combination patent portfolio, followed by immune checkpoint and DNA damage response strategies.
DESTINY-Breast Trial Portfolio by Disease Setting
The DESTINY-Breast programme now spans five documented phase III settings, with early-stage trials (DB05 and DB11) representing 40% of the named trial portfolio.
Documented T-DXd Combination Strategies from Patent Filings
Daiichi Sankyo's patent programme documents over 20 distinct combination strategies for T-DXd. The table below covers key mechanistic categories with specific patent references.
| Combination Partner | Mechanistic Class | Key Patent Reference | Breast Cancer Setting |
|---|---|---|---|
| Taxane | Chemotherapy | WO2024118784A1 | Early-stage HER2+ (neoadjuvant / adjuvant) |
| Pertuzumab + Chemotherapy | HER2 dual blockade + chemo | WO2024057314A1 | Neoadjuvant, adjuvant, metastatic |
| PARP Inhibitor | DNA Damage Response | US20230390407A1 | HER2+ breast cancer |
| ATM Inhibitor | DNA Damage Response | US20220280650A1 | HER2+ breast cancer |
| CDK4/6 Inhibitor | Cell Cycle / Kinase | WO2024100649A1 | HER2+ breast cancer |
| CDK4/6 Inhibitor + Endocrine Agent | Cell Cycle + Endocrine | WO2024100650A1 | HER2+ breast cancer |
| CDK2 Inhibitor | Cell Cycle / Kinase | WO2024100648A1 | HER2+ breast cancer |
| Anti-PD-1 Antibody | Immune Checkpoint | WO2023223265A1 | HER2+ breast cancer |
Need competitive intelligence on HER2-targeted ADC combinations?
PatSnap Eureka maps the full patent landscape across Daiichi Sankyo, AstraZeneca, Genentech, and emerging biosimilar filers.
Key Insights from the T-DXd Patent Landscape
Patent filings from 2022 to 2024 reveal Daiichi Sankyo's strategic positioning of T-DXd across the full breast cancer treatment continuum.
Early-Stage Is a Priority, Not an Afterthought
Patent US20240115717A1 and WO2024057313A1 (both filed in 2024) explicitly claim methods for treating early breast cancer with T-DXd, including neoadjuvant treatment of HER2-positive and HER2-low early breast cancer, and adjuvant treatment in patients with residual disease after neoadjuvant chemotherapy. This signals a deliberate move to capture the curative-intent market.
HER2-Low Extends the Addressable Population
HER2-low breast cancer is defined by immunohistochemical scores of 1+ or 2+ (without FISH amplification). Patent US20240091373A1 discloses methods for treating HER2-low breast cancer with T-DXd, with clinical evidence of anti-tumor activity observed in DESTINY-Breast04 data. DESTINY-Breast11 extends this to the early-stage neoadjuvant setting — dramatically expanding the eligible patient population.
Tucatinib Combination Addresses Brain Metastases
EP4392068A1 and WO2024220564A1 document the combination of T-DXd and tucatinib (a HER2-targeted tyrosine kinase inhibitor) for treating HER2-positive breast cancer, including patients with brain metastases. This combination is being evaluated in earlier line settings for HER2-positive metastatic disease, with DESTINY-Breast12 specifically addressing the brain metastasis population.
Immune Checkpoint Combinations Signal Immuno-Oncology Integration
Multiple patent families document combinations of T-DXd with anti-PD-1 (WO2023223265A1), anti-PD-L1 (US20230321254A1), anti-CTLA4 (WO2024018427A1), and anti-TIGIT antibodies (WO2024018426A1). The combination with an anti-TIGIT antibody is also paired with an anti-PD-L1 antibody in a triplet strategy, reflecting the broader trend of ADC + immunotherapy combinations in breast cancer.
How PatSnap Eureka Accelerates T-DXd Intelligence
The T-DXd patent landscape is complex, fast-moving, and strategically critical. With over 40 combination patent families filed by Daiichi Sankyo alone between 2022 and 2024, manual monitoring is insufficient for R&D teams, business development professionals, and patent attorneys working in the HER2-targeted therapy space.
PatSnap Eureka uses AI to search, analyse, and summarise the global patent and literature landscape for T-DXd and the broader life sciences ADC ecosystem. Users can identify new combination filings the day they publish, track prosecution status across jurisdictions, and map freedom-to-operate risks for biosimilar development programmes.
According to EMA regulatory guidance, early-stage breast cancer trials require robust evidence packages that span clinical, translational, and IP dimensions. PatSnap Eureka integrates patent data with analytics tools to help teams build that evidence in one platform.
For teams building biosimilar or next-generation ADC programmes, PatSnap's open API enables integration of patent monitoring directly into existing R&D workflows and data pipelines.
T-DXd Early-Stage HER2+ Breast Cancer — Key Questions Answered
Trastuzumab deruxtecan (T-DXd, brand name Enhertu) is an antibody-drug conjugate (ADC) comprising an anti-HER2 antibody linked to the topoisomerase I inhibitor payload DXd (an exatecan derivative) via a tetrapeptide-based cleavable linker. It is co-developed by Daiichi Sankyo and AstraZeneca and is characterized by a drug-to-antibody ratio (DAR) of approximately 7–8.
DESTINY-Breast05 and DESTINY-Breast11 are key phase III clinical trials evaluating trastuzumab deruxtecan in early breast cancer settings, including neoadjuvant treatment of HER2-positive and HER2-low early breast cancer, as well as adjuvant treatment in patients with residual disease after neoadjuvant chemotherapy.
Patent filings from Daiichi Sankyo and AstraZeneca document combination strategies pairing T-DXd with taxanes, pertuzumab, CDK4/6 inhibitors, CDK2 inhibitors, endocrine agents, immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA4, anti-TIGIT), PARP inhibitors, ATM inhibitors, PI3K inhibitors, AKT inhibitors, tucatinib, VEGF/VEGFR inhibitors, and HER3-DXd (patritumab deruxtecan), among others.
Yes. HER2-low breast cancer is defined by immunohistochemical scores of 1+ or 2+ (without FISH amplification). Clinical evidence of anti-tumor activity in HER2-low patients was observed in DESTINY-Breast04 data, and patent disclosures from Daiichi Sankyo and AstraZeneca include methods for treating HER2-low breast cancer with trastuzumab deruxtecan in both early-stage and metastatic settings.
Trastuzumab deruxtecan delivers the cytotoxic topoisomerase I inhibitor DXd directly to HER2-expressing cancer cells via the anti-HER2 antibody trastuzumab. The tetrapeptide-based cleavable linker enables selective release of the payload inside the tumor cell. The high drug-to-antibody ratio of approximately 7–8 is designed to optimize anti-tumor activity while maintaining an acceptable toxicity profile. A bystander killing effect on neighboring HER2-low or HER2-negative cells has also been described.
DESTINY-Breast09 and DESTINY-Breast12 trial designs are referenced in patent disclosures related to treatment of HER2-positive breast cancer in earlier line settings, including first-line metastatic disease. DESTINY-Breast09 examines T-DXd as a first-line option, while DESTINY-Breast12 focuses on patients with brain metastases.
Still have questions about T-DXd patents or DESTINY-Breast trial intelligence? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About T-DXdAccelerate Your T-DXd and HER2+ Breast Cancer Research
Join 18,000+ innovators already using PatSnap Eureka to monitor ADC patent landscapes, track DESTINY-Breast trial developments, and identify combination therapy opportunities.
References
- Daiichi Sankyo / AstraZeneca — US20240115717A1: Anti-HER2 ADC Treatment of Early Breast Cancer (2024)
- Daiichi Sankyo / AstraZeneca — WO2024057313A1: Anti-HER2 ADC Treatment of Breast Cancer (2024)
- Daiichi Sankyo / AstraZeneca — WO2024118784A1: Combination Anti-HER2 ADC and Taxane for Breast Cancer (2024)
- Daiichi Sankyo / AstraZeneca — WO2024057314A1: Anti-HER2 ADC Combination Treatment of Breast Cancer (2024)
- Daiichi Sankyo / AstraZeneca — US20240091373A1: Anti-HER2 ADC Treatment of HER2-Low Breast Cancer (2024)
- Daiichi Sankyo / AstraZeneca — US11872289B2: Antibody-Drug Conjugate Comprising Anti-HER2 Antibody and DXd (2024)
- Daiichi Sankyo / AstraZeneca — EP4392068A1: T-DXd + Tucatinib for HER2-Positive Breast Cancer (2024)
- Seagen / Daiichi Sankyo / AstraZeneca — WO2024220564A1: T-DXd and Tucatinib for HER2+ Cancers (2024)
- Daiichi Sankyo — WO2023223265A1: Combination Anti-HER2 ADC and Anti-PD-1 Antibody (2023)
- Daiichi Sankyo — WO2024018426A1: Combination Anti-HER2 ADC and Anti-TIGIT Antibody (2024)
- Daiichi Sankyo — US20230390407A1: Combination ADC and PARP Inhibitor (2023)
- Daiichi Sankyo — WO2024100649A1: Combination Anti-HER2 ADC and CDK4/6 Inhibitor (2024)
- Genentech — WO2023225336A1: Methods for Treating Breast Cancer Using Anti-HER2 ADC (2023)
- U.S. Food and Drug Administration (FDA) — Enhertu (trastuzumab deruxtecan) Approval Information
- ClinicalTrials.gov — DESTINY-Breast Phase III Trial Registry
- European Medicines Agency (EMA) — Enhertu Assessment and Regulatory Guidance
All patent data and analysis on this page is sourced from the PatSnap patent database and the references above. Patent filings are analysed via PatSnap's proprietary innovation intelligence platform. This page does not constitute medical or legal advice.
PatSnap Eureka searches patents and research to answer instantly.